Orexigen Therapeutics Overview
- Year Founded
-
2002
- Status
-
Private
- Employees
-
132
- Latest Deal Type
-
M&A
- Financing Rounds
-
13
- Investments
-
1
Orexigen Therapeutics General Information
Description
Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity.
Contact Information
Website
www.orexigen.comCorporate Office
- 3344 North Torrey Pines Court
- Suite 200, La Jolla
- San Diego, CA 92037
- United States
Corporate Office
- 3344 North Torrey Pines Court
- Suite 200, La Jolla
- San Diego, CA 92037
- United States
Orexigen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Orexigen Therapeutics Comparisons
Industry
Financing
Details
Orexigen Therapeutics Competitors (35)
One of Orexigen Therapeutics’s 35 competitors is Regeneron Pharmaceuticals, a Formerly VC-backed company based in Tarrytown, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| TG Therapeutics | Corporation | Morrisville, NC | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| Vericel | Formerly PE-Backed | Burlington, MA |
Orexigen Therapeutics Patents
Orexigen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2020037593-A | Compositions and methods for reducing major adverse cardiovascular events | Active | 06-Dec-2013 | ||
| WO-2015085044-A1 | Compositions and methods for reducing major adverse cardiovascular events | Inactive | 06-Dec-2013 | ||
| JP-2026088122-A | Method of treating overweight and obesity | Pending | 06-Jun-2012 | ||
| JP-2018158945-A | Methods of treating overweight and obesity | Active | 06-Jun-2012 | ||
| JP-2021080274-A | Methods of treating overweight and obesity | Pending | 06-Jun-2012 | A61K31/485 |
Orexigen Therapeutics Signals
Orexigen Therapeutics Investments (1)
Orexigen Therapeutics’s most recent deal was a Corporate Asset Purchase with Contrave (US rights) for . The deal was made on 15-Mar-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Contrave (US rights) | 15-Mar-2016 | Corporate Asset Purchase | Pharmaceuticals |
Orexigen Therapeutics FAQs
-
When was Orexigen Therapeutics founded?
Orexigen Therapeutics was founded in 2002.
-
Where is Orexigen Therapeutics headquartered?
Orexigen Therapeutics is headquartered in San Diego, CA.
-
What is the size of Orexigen Therapeutics?
Orexigen Therapeutics has 132 total employees.
-
What industry is Orexigen Therapeutics in?
Orexigen Therapeutics’s primary industry is Pharmaceuticals.
-
Is Orexigen Therapeutics a private or public company?
Orexigen Therapeutics is a Private company.
-
What is the current valuation of Orexigen Therapeutics?
The current valuation of Orexigen Therapeutics is .
-
What is Orexigen Therapeutics’s current revenue?
The current revenue for Orexigen Therapeutics is .
-
How much funding has Orexigen Therapeutics raised over time?
Orexigen Therapeutics has raised $379M.
-
Who are Orexigen Therapeutics’s competitors?
Regeneron Pharmaceuticals, Pfizer (Vienna), TG Therapeutics, Pfizer Pakistan, and Vericel are some of the 35 competitors of Orexigen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process